The global women’s health therapeutics market size is expected to reach USD 56.8 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 4.0% from 2024 to 2030. Entry of effective drugs, a rise in awareness about early diagnosis and treatment, along with prevalence of chronic diseases are among the key factors likely to drive the market during the forecast period.
The women’s health therapeutics market is expected to witness high growth in the forthcoming years due to increasing investment by key market players to fulfill demand in areas of infection, cancer, and pregnancy-related complications. In October 2016, Prelude Fertility, Inc. received USD 200 million from the Reproductive Biology Associates (RBA) and My Egg Bank North America (MEB) that focuses on providing fertility services and treatment to people with delayed childbirth. Juneau Biosciences, LLC has deployed USD 35 million until 2017 towards development of molecular diagnostics and therapeutics for endometriosis (uterus) conditions.
In January 2018, Melinta Therapeutics, Inc. acquired The Medicines Company’s infectious diseases business. This acquisition would help to the former expand its portfolio by offering life-saving treatment options. In November 2017, Biocon launched KRABEVA, a biosimilar used for the treatment of metastatic colorectal, cervical, ovarian, and brain cancer. Increasing investments by top market players are anticipated to propel the global market over the forecast period.
Get a preview of the latest developments in the Womens Health Therapeutics Market! Download your FREE sample PDF today and explore key data and trends
There is significant unmet need associated with treatment options for female sexual dysfunction. Currently, there are no Food and Drug Administration (FDA)-approved drugs for the treatment of female sexual dysfunction and many promising molecules are in late stage of development phase. Some of these molecules include LibiGel by BioSante Pharmaceuticals and Femprox by Apricus Bio, currently in Phase III and Phase II of clinical trials respectively in U.S.
Women's Health Therapeutics Market Report Highlights
By type, infection accounted for the largest market share in 2023 and is expected to maintain its dominance during the forecast period due to rising drug approvals, availability of diagnostic tests and treatments, and high incidence of infectious diseases
- Ovarian cancer is anticipated to be the fastest-growing sub-segment of oncology during the forecast period due to high prevalence of ovarian cancer and approval of new and improved drugs
- North America is expected to maintain its dominance in the coming years due to high awareness about women’s health, increase in number of advanced diagnostic and treatment methods, mergers and acquisitions by market players, and rise in infections and cancer cases
- Asia Pacific is likely to witness significant growth over the next decade due to improving healthcare facilities, increase in commercialization and approval of products, and investment by market players
List of Key Players of Women's Health Therapeutics Market
- Bayer AG
- Pfizer, Inc.
- Cipla Inc.
- Orchid Pharma.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical
- Hoffmann-La Roche Ltd.
- AbbVie
- Axena Health
Gather more insights about the market drivers, restrains and growth of the Global Womens Health Therapeutics Market
COVID-19 Impact Analysis on Women Health Therapeutics Market report published by Value Market Research provides a detailed market analysis comprising market size, share, value, growth and trends for the period 2020-2027.
The report encompasses data regarding market share and recent developments by key players.
Moreover, this market report also covers regional and country markets in detail.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the women health therapeutics market include Abbott Laboratories, Amgen, Inc., Astellas Pharma Inc., Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck& Co., Inc., Novartis International AG, Novogyne Pharmaceuticals, Novo Nordisk A/S, Pfizer, Inc.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Women Health Therapeutics Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/women-health-therapeutics-market/download-sampleMarket DynamicsRising awareness about women's health and its treatment is the key market driver for the growth of the women's health therapeutics market.
High investments made to meet the unmet demands of drugs related to the treatment of issues like infections, cancer, pregnancy, etc is also one of the major driving force responsible for the market growth of women health therapeutics.
This report studies the global market size of Womens Health in key regions like North America, Europe,Asia Pacific, Central & South America and Middle East & Africa, focuseson the consumption of Womens Health inthese regions.
This report also studies the global market status, competitionlandscape, market share, growth rate, future trends, market drivers,opportunities and challenges, sales channels, distributors and Porter’s FiveForces Analysis.
Market size split by Region
Rest of Central & South America
Do Inquiry BeforeAccessing Global Womens Health Market Report at https://www.orbisresearch.com/contacts/enquiry-before-buying/2376761 .
Focuses on the key global Womens Health manufacturers, to define, describe and analyzethe sales volume, value, market share, market competition landscape, SWOTanalysis and development plans in next few years.
